Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Catalent and UMN Pharma Announce Collaboration

Published: Thursday, December 20, 2012
Last Updated: Thursday, December 20, 2012
Bookmark and Share
UMN Pharma will produce a number of biosimilars using Catalent’s GPEx cell lines.

Catalent Pharma Solutions and UMN Pharma Inc. have announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell lines using Catalent’s proprietary GPEx® technology.

The development and manufacturing programs will benefit from the GPEx technology producing very stable and high yielding cell lines.

Under the agreement, UMN Pharma and its subsidiary UNIGEN, which is a contract manufacturer, will produce a number of biosimilars using Catalent’s GPEx cell lines.

UMN Pharma, separately, will build an alliance of pharmaceutical companies for product development including clinical trials, marketing and sales.

UMN Pharma plans to begin multiple biosimilar projects with their alliance companies for the Asian market on an ongoing basis.

“There are great synergies between UMN Pharma and Catalent in terms of technologies, business structure, speed and culture,” commented Masahiro Michishita, Executive Chairman of UMN Pharma.

Michishita continued, “Harnessing Catalent’s broad biologics development and cell construction expertise gives UMN Pharma a unique platform to grow our biosimilars business globally.”

Barry Littlejohns, Catalent’s Business Unit President, added, “This agreement will allow Catalent to continue to grow its biologics development and manufacturing interests of multiple biosimilars and NBEs, particularly in the Asian market. UMN Pharma’s ambitious expansion plans reflect Catalent’s strategy for growth in what we consider to be a key market.”

Hans-Joachim Rohe, President of Catalent Japan added: “We are very excited to offer a continuously expanding range of Catalent services to our customers in Japan. With the growing demand for Catalent’s GPEx technology we enforce our position as leading supplier of drug delivery solutions and expert services.”

Founded in 2004, UMN Pharma now has three manufacturing facilities in Japan focused on the development of influenza vaccines based on insect cells.

Supported by the Japanese government, UMN Pharma currently has three 600L bioreactors for influenza vaccine production.

In response to the emerging demand for influenza vaccines, also for new biological entities (NBEs) and biosimilars, it has commissioned two additional 21,000L units in Gifu, to be operational by 2013. UMN Pharma will then add another two 21,000L facility by 2016.

Catalent’s biologics group has expressed over 360 cell lines for clients, with dozens of on-going clinical trails throughout the world and two products utilizing the GPEx technology currently on the market.

A new facility with 500L and 1000L single use bioreactors for cGMP manufacturing will be opening in Madison, Wisconsin, USA in spring 2013.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Catalent Biologics, Moderna Therapeutics Collaborate
Collaboration aims to support near-term clinical GMP mRNA manufacturing efforts for Phase 1/2 clinical studies of the company’s mRNA personalized cancer vaccines.
Saturday, October 22, 2016
Catalent To Acquire Pharmatek
The acquisition adds expanded drug development services and spray drying technology.
Wednesday, September 14, 2016
Catalent, Zumutor Collaborate
Collaboration aims to develop antibodies with enhanced ADCC activity.
Friday, August 05, 2016
Catalent, Palatin Technologies Announce Agreement
Partnership aims to support the product launch of Palatin’s bremelanotide pen injector product, which is used to treat FSD.
Thursday, July 07, 2016
Catalent Launches FastChain Service
Company has announced the launch of its FastChain service to meet increasing need for speed & flexibility in global clinical trials.
Thursday, June 30, 2016
Catalent Invests $4.6M To Further Expand Asia–Pacific Clinical Trials
Company provide of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services.
Friday, February 05, 2016
Catalent Announces Appointment of Sally Langa
Appointment of Ms. Langa as new Vice President of Development and Analytical Services.
Friday, January 29, 2016
Catalent to Open New Clinical Supply Facility in Japan
Construction is expected to be validated and operational in the second quarter of 2016.
Thursday, January 21, 2016
Catalent Announces Research Collaboration with Roche
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent, Roche Collaborate On SMARTag™
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent Biologics Announces the Appointment of Kevin Hambly
Company appoints Mr. Hambly to the position of Vice President, Business Development and Licensing.
Tuesday, December 15, 2015
Catalent Biologics Expands Capabilities
Company announces multi-site expansion of its analytical and process development capabilities.
Thursday, November 26, 2015
Catalent Biologics Adds New Technology Platform
Company has signed an exclusive licensing agreement with Excelimmune to access ACT platform.
Thursday, July 09, 2015
Catalent Awarded Grant as Part of Vaccine Research Consortium
Goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
Friday, April 24, 2015
Catalent & Sanofi to Collaborate
Collaboration on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies.
Thursday, January 22, 2015
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
MRSA Uses Decoys to Evade a Last-Resort Antibiotic
Researchers at Imperial College London have discovered that MRSA releases decoy molecules that allow them to escape being killed by the antibiotic.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Zika Virus Infection Alters Human and Viral RNA
Researchers have discovered that Zika infections results in human and viral genetic modification.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos